Company intelligence / Profile preview

Retension Pharmaceuticals

Falls Church, Virginia, United Statesretensionpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

RTN-001 has been studied in over 265 human subjects, including two Phase 2 studies in patients with uncontrolled hypertension. The drug was well-tolerated and demonstrated clinically significant blood pressure lowering effects comparable to established antihypertensives, with reductions in central blood pressure.

Therapeutic areas: Cardiovascular
Modalities: Small molecules (specifically PDE5 inhibitors)
Industry: Biotech

Drug pipeline

1 asset

RTN-001

Partnerships

Exclusive worldwide license from Sanofi S.A.

Beyond the preview

Go deeper on Retension Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retension Pharmaceuticals.

Explore the full profile